Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer
October 02 2017 - 4:05PM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the promotion of Dr. Ganesh
Kaundinya to Chief Operating Officer. Dr. Kaundinya, who assumed
his new position effective September 25, 2017, will also continue
to serve as Chief Scientific Officer and report directly to Craig
Wheeler, Momenta’s President and Chief Executive Officer.
“As one of our founders, Ganesh has been a
cornerstone at Momenta since its inception. Ganesh has achieved a
great track record of success and in this new role I believe his
passion for the business, our strategic partnerships, and the
impact we can have on patients’ lives will play an even more
integral role in driving our business forward,” said Craig Wheeler,
President and CEO, Momenta Pharmaceuticals.
In addition to his role as Chief Scientific
Officer, Dr. Kaundinya will oversee the operational management of
research and development, manufacturing, commercial activities, and
program and alliance management.
Ganesh Kaundinya added, “I am very excited to
take on this expanded role at Momenta as we continue to advance our
robust portfolio of biosimilar and novel drug candidates that have
the potential to address the unmet medical needs of the patients we
look to serve, as well as create significant value for our
shareholders and employees.”
Prior to founding Momenta, Dr. Kaundinya was a
member of the MIT faculty where he pioneered research in the areas
of analytical techniques for complex molecules and extracellular
matrix regulation of cell biology. He also served as the
Director of Bioinformatics for the Consortium for Functional
Glycomics, a multi-million dollar NIH initiative to study the role
of complex sugars in biology. Dr. Kaundinya received both his
M.S. and Ph.D. in Chemical Engineering from Massachusetts Institute
of Technology.
About MomentaMomenta
Pharmaceuticals is a biotechnology company specializing in the
detailed structural analysis of complex drugs and is headquartered
in Cambridge, MA. Momenta is applying its technology to
the development of generic versions of complex drugs, biosimilar
and potentially interchangeable biologics, and to the discovery and
development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about Dr.
Kaundinya’s expected impact and duties, and statements about the
Company’s drug candidates and the ability of the Company’s drug
candidates to address the unmet medical needs of patients and
create significant value for our shareholders and employees.
Forward-looking statements may be identified by words such as
"believe," "continue," "potential," "will," and other similar words
or expressions, or the negative of these words or similar words or
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, including those
referred to under the section "Risk Factors" in the Company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2017,
filed with the Securities and Exchange Commission, as well as other
documents that may be filed by the Company from time to time with
the Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements
discussed in or implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
INVESTOR CONTACT:Sarah CarmodyMomenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com
MEDIA CONTACT:Karen SharmaMacDougall Biomedical
Communications1-781-235-3060Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Sep 2023 to Sep 2024